CORRELATION BETWEEN VISUAL CLUES, OBJECTIVE ARCHITECTURAL FEATURES, AND INTEROBSERVER AGREEMENT IN PROSTATE-CANCER

被引:42
作者
DILORETO, C
FITZPATRICK, B
UNDERHILL, S
KIM, DH
DYTCH, HE
GALERADAVIDSON, H
BIBBO, M
机构
[1] UNIV CHICAGO, DEPT PATHOL,CYTOPATHOL SECT,5841 S MARYLAND AVE, BOX 449, CHICAGO, IL 60637 USA
[2] UNIV CHICAGO, DEPT OBSTET & GYNECOL, CHICAGO, IL 60637 USA
[3] UNIV SEVILLE, DEPT PATHOL, SEVILLE, SPAIN
关键词
GRADING; PROSTATE CANCER; MORPHOMETRY; ARCHITECTURAL FEATURES; GLEASON GRADE; REPRODUCIBILITY; CARCINOMA;
D O I
10.1093/ajcp/96.1.70
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Three pathologists evaluated a number of designated architectural features to assign grades to 41 cases of well- to moderately differentiated adenocarcinoma, and their opinions were compared. The consensus opinion was obtained and evaluated against objective measurements of glandular architecture that were obtained by morphometric techniques. The observers agreed on gland size, gland uniformity, and the number of glands per field in only 49%, 31%, and 39% of cases, respectively. There were significant differences in the Gleason grades assigned by observers. Paired matching of individual Gleason grades showed agreement among observers in 44% (18 of 41), 56% (23 of 41), and 75% (31 of 41) of cases, respectively. This level of interobserver disagreement occurred even though cases with predominant patterns were selected carefully and those with variable patterns were excluded. A direct relationship appears to exist between increasing Gleason grade and increasing glandular variability, and there is an inverse relationship between Gleason grade, gland lumen area, and the number of glandular nuclei, as assessed by a group of pathologists.
引用
收藏
页码:70 / 75
页数:6
相关论文
共 13 条
  • [1] [Anonymous], 1925, Minn. Med
  • [2] BARTELS PH, 1989, AM J CLIN PATHOL, V91, pS7
  • [3] BIBBO M, 1990, ANAL QUANT CYTOL, V12, P85
  • [4] BIBBO M, 1990, ANAL QUANT CYTOL, V12, P229
  • [5] BOCKING A, 1982, CANCER, V50, P288, DOI 10.1002/1097-0142(19820715)50:2<288::AID-CNCR2820500220>3.0.CO
  • [6] 2-S
  • [7] BRAWN PN, 1982, CANCER-AM CANCER SOC, V49, P525, DOI 10.1002/1097-0142(19820201)49:3<525::AID-CNCR2820490321>3.0.CO
  • [8] 2-M
  • [9] Gleason DF., 1977, UROLOGIC PATHOLOGY P, P171
  • [10] GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125